# ClinicalTrials.gov record NCT07441252

> PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07441252-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07441252-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07441252-maridebart-cafraglutide-v1.json
- Content SHA-256: `1129072978410d83e5f0f54bd6c3b9a952416f0e5ec6d6df6ac79f837692c17c`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07441252 ([`ctg-observation-nct07441252-2026-06-18-204e72018406`](#source-ctg-observation-nct07441252-2026-06-18-204e72018406))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07441252-2026-06-18-204e72018406`](#source-ctg-observation-nct07441252-2026-06-18-204e72018406))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07441252-2026-06-18-204e72018406`](#source-ctg-observation-nct07441252-2026-06-18-204e72018406))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07441252-2026-06-18-204e72018406`](#source-ctg-observation-nct07441252-2026-06-18-204e72018406))

## Sources

<a id="source-ctg-observation-nct07441252-2026-06-18-204e72018406"></a>
- **ClinicalTrials.gov record NCT07441252 · retained source version 2026-06-18:204e72018406561b9fd2daba448608e487fe397757a26dd95c32fdcdfedd48bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07441252) (`ctg-observation-nct07441252-2026-06-18-204e72018406`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07441252." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07441252-maridebart-cafraglutide-v1.json SHA-256: 1129072978410d83e5f0f54bd6c3b9a952416f0e5ec6d6df6ac79f837692c17c.